Companies

CARGO Therapeutics Inc

NASDAQ: CRGX
$4.47
▲ $0.00 (+0.00%) today
Markets closed · 6:52pm ET

About Cargo Therapeutics

CARGO Therapeutics Inc is a trailblazer in the biotechnology sector, focusing on developing advanced treatments for cancer through chimeric antigen receptor (CAR) T-cell therapies. Its flagship project, CRG-022, aims to combat B-cell malignancies by targeting CD22, a crucial tumor antigen. Additionally, the company is working on CRG-023, a pioneering tri-specific CAR T therapy that targets three B-cell antigens simultaneously. Founded in 2019 and based in San Mateo, California, CARGO Therapeutics is dedicated to revolutionizing cancer treatment.

CRGX Coverage

Frequently Asked Questions

What does Cargo Therapeutics do?

CARGO Therapeutics Inc is a trailblazer in the biotechnology sector, focusing on developing advanced treatments for cancer through chimeric antigen receptor (CAR) T-cell therapies. Its flagship project, CRG-022, aims to combat B-cell malignancies by targeting CD22, a crucial tumor antigen.